378 related articles for article (PubMed ID: 28836267)
1. When and How Can Real World Data Analyses Substitute for Randomized Controlled Trials?
Franklin JM; Schneeweiss S
Clin Pharmacol Ther; 2017 Dec; 102(6):924-933. PubMed ID: 28836267
[TBL] [Abstract][Full Text] [Related]
2. Trial designs using real-world data: The changing landscape of the regulatory approval process.
Baumfeld Andre E; Reynolds R; Caubel P; Azoulay L; Dreyer NA
Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1201-1212. PubMed ID: 31823482
[TBL] [Abstract][Full Text] [Related]
3. Synergies From Integrating Randomized Controlled Trials and Real-World Data Analyses.
Najafzadeh M; Gagne JJ; Schneeweiss S
Clin Pharmacol Ther; 2017 Dec; 102(6):914-916. PubMed ID: 29034448
[TBL] [Abstract][Full Text] [Related]
4. Real-world evidence to support regulatory decision-making for medicines: Considerations for external control arms.
Burcu M; Dreyer NA; Franklin JM; Blum MD; Critchlow CW; Perfetto EM; Zhou W
Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1228-1235. PubMed ID: 32162381
[TBL] [Abstract][Full Text] [Related]
5. Assessing strength of evidence for regulatory decision making in licensing: What proof do we need for observational studies of effectiveness?
Slattery J; Kurz X
Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1336-1340. PubMed ID: 32301230
[TBL] [Abstract][Full Text] [Related]
6. Use of real-world evidence in regulatory decisions for rare diseases in the United States-Current status and future directions.
Wu J; Wang C; Toh S; Pisa FE; Bauer L
Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1213-1218. PubMed ID: 32003065
[TBL] [Abstract][Full Text] [Related]
7. A Statistical Roadmap for Journey from Real-World Data to Real-World Evidence.
Fang Y; Wang H; He W
Ther Innov Regul Sci; 2020 Jul; 54(4):749-757. PubMed ID: 32557297
[TBL] [Abstract][Full Text] [Related]
8. Real-world Data for Clinical Evidence Generation in Oncology.
Khozin S; Blumenthal GM; Pazdur R
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059439
[TBL] [Abstract][Full Text] [Related]
9. Use of Real-world Data for New Drug Applications and Line Extensions.
Bolislis WR; Fay M; Kühler TC
Clin Ther; 2020 May; 42(5):926-938. PubMed ID: 32340916
[TBL] [Abstract][Full Text] [Related]
10. What Is Real-World Data? A Review of Definitions Based on Literature and Stakeholder Interviews.
Makady A; de Boer A; Hillege H; Klungel O; Goettsch W;
Value Health; 2017; 20(7):858-865. PubMed ID: 28712614
[TBL] [Abstract][Full Text] [Related]
11. Using real-world evidence in haematology.
Passamonti F; Corrao G; Castellani G; Mora B; Maggioni G; Della Porta MG; Gale RP
Best Pract Res Clin Haematol; 2024 Mar; 37(1):101536. PubMed ID: 38490764
[TBL] [Abstract][Full Text] [Related]
12. The importance of collecting structured clinical information on multiple sclerosis.
Ziemssen T; Hillert J; Butzkueven H
BMC Med; 2016 May; 14():81. PubMed ID: 27246898
[TBL] [Abstract][Full Text] [Related]
13. Secondary use of randomized controlled trials to evaluate drug safety: a review of methodological considerations.
Hammad TA; Pinheiro SP; Neyarapally GA
Clin Trials; 2011 Oct; 8(5):559-70. PubMed ID: 21878445
[TBL] [Abstract][Full Text] [Related]
14. Evaluating the Use of Nonrandomized Real-World Data Analyses for Regulatory Decision Making.
Franklin JM; Glynn RJ; Martin D; Schneeweiss S
Clin Pharmacol Ther; 2019 Apr; 105(4):867-877. PubMed ID: 30636285
[TBL] [Abstract][Full Text] [Related]
15. Replication of Oncology Randomized Trial Results using Swedish Registry Real World-Data: A Feasibility Study.
Jemielita T; Widman L; Fox C; Salomonsson S; Liaw KL; Pettersson A
Clin Pharmacol Ther; 2021 Dec; 110(6):1613-1621. PubMed ID: 34549809
[TBL] [Abstract][Full Text] [Related]
16. Replication of Randomized, Controlled Trials Using Real-World Data: What Could Go Wrong?
Thompson D
Value Health; 2021 Jan; 24(1):112-115. PubMed ID: 33431143
[TBL] [Abstract][Full Text] [Related]
17. Building reliable evidence from real-world data: Needs, methods, cautiousness and recommendations.
Corrao G; Cantarutti A
Pulm Pharmacol Ther; 2018 Dec; 53():61-67. PubMed ID: 30253238
[TBL] [Abstract][Full Text] [Related]
18. It is important to note that RWD will never replace the more traditional and more robust RCT data; however, the emerging trend is to incorporate data that are more generalizable. Introduction.
Mullins CD; Sanchez RJ
J Manag Care Pharm; 2011; 17(9 Suppl A):S03-4. PubMed ID: 22074667
[TBL] [Abstract][Full Text] [Related]
19. Sources of Safety Data and Statistical Strategies for Design and Analysis: Real World Insights.
Marchenko O; Russek-Cohen E; Levenson M; Zink RC; Krukas-Hampel MR; Jiang Q
Ther Innov Regul Sci; 2018 Mar; 52(2):170-186. PubMed ID: 29714518
[TBL] [Abstract][Full Text] [Related]
20. Balancing the Optimal and the Feasible: A Practical Guide for Setting Up Patient Registries for the Collection of Real-World Data for Health Care Decision Making Based on Dutch Experiences.
de Groot S; van der Linden N; Franken MG; Blommestein HM; Leeneman B; van Rooijen E; Koos van der Hoeven JJ; Wouters MW; Westgeest HM; Uyl-de Groot CA
Value Health; 2017 Apr; 20(4):627-636. PubMed ID: 28408005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
